Clinical trials /

TAS-102 (Lonsurf) and Celecoxib

RecruitingPhase 2InterventionalNCT05343013 ↗

This is a study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.

Sponsor
M.D. Anderson Cancer Center
Planned enrollment
25 participants
Start date
June 6, 2022
Primary completion
May 15, 2027 (est.)
Minimum age
18 Years
Interventions
TAS-102

Official title: TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

This is a Phase 2 study to measure the level of circulating tumor DNA (ctDNA) in the blood of colorectal cancer patients after 6 months of receiving TAS-102 therapy.

Key Eligibility Criteria

  • Patients with confirmed stage II-IV colon or rectal cancer
  • Patients must:
    • have completed all planned curative intent therapies that must include ≥ 3 months of oxaliplatin containing chemotherapy
    • have no radiographic evidence of disease within 28 days of positive ctDNA assay
    • have a ctDNA positive assay

Treatment

Drug: TAS-102 (Lonsurf), a thymidine phosphorylase inhibitor

Drug: Celecoxib, NSAID

ClinicalTrials.gov ID NCT05343013

Where this trial is offered

  • MD Anderson Cancer CenterHouston, Texas
    Recruiting

Status, sites, and study facts from ClinicalTrials.gov, last posted March 6, 2026 and refreshed here September 5, 2026.View the full record for NCT05343013.